Anti-Mouse osteopontin/SPP1 Antibody (103D6)
Based on 1 Customer Validation
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models.
For research use only. We do not sell to patients.
- Purity : 99.76%
- Molecular Weight:147.09 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG2c kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
osteopontin/SPP1
In Vitro
Anti-Mouse osteopontin/SPP1 Antibody (103D6) (24 h) significantly increases the lytic activity of a tumor-specific CTL in lysing the target CT26 tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse osteopontin/SPP1 Antibody (103D6) (200 μg/mouse, before CBDL operation and at day 0, 2, day 5 and day 7 following CBDL) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Colon tumor mice models injected with CT 26 cells (BALB/c, 2-3 months)[1]
-
Dosage:200 μg/mouse
-
Administration:Subcutaneously injection, every 3 days for 14 days
-
Result:Suppressed CT26 tumor growth.
-
Animal Model:Common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models (C57BL6/J, male, 8 weeks)[2]
-
Dosage:200 μg/mouse
-
Administration:Before CBDL operation and at day 2, day 5 and day 7 following CBDL
-
Result:Showed lower serum alanine transaminase.
Had less ductular reaction, necrosis and fibrosis.
Decreased expression levels of inflammatoryand fibrotic markers.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay, Research in vivo
Verified Bioactivity
-
Immobilized Osteopontin/OPN Protein, Mouse (HEK293, His) (HY-P78358) can bind Anti-Mouse osteopontin/SPP1 Antibody (103D6). The EC50 for this effect is 3.28 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 147.09 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse osteopontin/SPP1 Antibody (103D6)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Klement JD, et al. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel). 2021 Feb 28;13(5):1006. [Content Brief]
[2]. De Muynck K, et al. Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis. Hepatology. 2024 Feb 1;79(2):269-288. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse osteopontin/SPP1 Antibody (103D6) Related Classifications
HY-P990116 Related Classifications
Powered by Bioz